Clear Search

Showing 34 results for “SLE” published 2022.

May 2022

High Systemic Type I Interferon Activity Is Associated with Active Class III/IV Lupus Nephritis

The Journal of Rheumatology 2022; 49:388–97 DOI 10.3899/jrheum.210391

Iwamoto, et al. aimed to determine the association of serum IFN activity with subtypes of lupus nephritis. This study suggests that systemic high type I IFN in SLE is involved in the pathogenesis of severe class III/IV LN and contributes to severe kidney involvement in European-American patients with SLE. However, this effect was independent of anti‑dsDNA antibody status and complement levels. Expression of type I IFN was not found to be clearly related to plasmacytoid dendritic cell infiltration, although it did directly stimulate podocytes to induce chemokines and molecules related to podocyte injury.

more…

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Ann Rheum Dis. 2022; 0:1–11. doi: 10.1136/annrheumdis-2021-221425

IFN-I signalling plays a key role in SLE pathogenesis, and anifrolumab has demonstrated inhibitory effects on IFN-I signalling in patients with SLE. Vital, et al. characterised efficacy and safety of anifrolumab in patients with moderate-to-severe SLE based on interferon gene signature, demographic and clinical subgroups using data pooled from the Phase III TULIP-1 and -2 trials.

more…

Efficacy and Safety of Obinutuzumab in Systemic Lupus Erythematosus Patients with Secondary Non-response to Rituximab

Rheumatology 2022;00:1–5 DOI.org/10.1093/rheumatology/keac150

Arnold, et al. present the first case series reporting the efficacy and safety of obinutuzumab in patients with treatment refractory SLE. The results indicate that, for this group of patients with limited treatment approaches, obinutuzumab could be a potential option.

more…

March 2022

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

Ann Rheum Dis. 2022;81(4):496–506 doi: 10.1136/annrheumdis-2021-221478

Despite not meeting the primary endpoint, this Phase II trial of anifrolumab in patients with active lupus nephritis (LN) demonstrates that anifrolumab IR is associated with numerical improvements over placebo across endpoints – including complete renal response – in patients with active LN.

more…

Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index

Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keab883

Easy-BILAG is a high-accuracy, time-efficient tool for recording BILAG-2004 disease activity in systemic lupus erythematosus (SLE).

Disease activity measurements in SLE are necessary for optimal patient care, treat-to-target approaches and clinical guidelines. However, administrative burden and potential frequency of errors with the current comprehensive disease activity instrument (BILAG-2004) limits its use in routine practice.

more…

February 2022

Evaluating the Construct of Damage in Systemic Lupus Erythematosus

Arthritis Care Res (Hoboken). 2021 Dec 28. Epub ahead of print

Study identifies shifts in the paradigm of systemic lupus erythematosus (SLE) damage and develops a unifying conceptual framework to inform development of a revised SLE Damage Index (SDI).

Shifts in the concept of damage in SLE have occurred with new insights into disease manifestations, diagnostics, and therapy. Consequently, there is a need for a revised SDI, to incorporate additional factors that contribute to damage accrual.

more…